PHS101 - Results From An on-Site Healthcare Provider Survey on Perceptions of Type 2 Diabetes Treatment

Abstract

To describe physician and healthcare provider (HCP) perception of type 2 diabetes (T2D) treatment using data drawn from an on-site, immediate-response questionnaire. 373 HCPs were polled on their experience, background, treatment satisfaction, and perceived challenges and unmet needs of treating patients with T2D. Of the 373 respondents, 48.4% (n= 181/373) were physicians, 48.3% identified as “Other”, and 3.3% were diabetic nurse specialists. 57.3% (n = 214/373) of respondents practiced in Europe, followed by 15.7% from Asia/Pacific, 10.0% from The Americas, and 4.3% from the UK. 33.1% (n = 123/373) of HCPs had more than 15 years of experience with T2D treatment. 38.5% (n = 144/373) of HCPs reported they were “Not Satisfied” with current available treatments for T2D, with only 3.1% (n = 12/373) reporting as “Very Satisfied.” 14.5% (n=54/373) of respondents reported a combination of factors, including route of administration, gastrointestinal side effects, weight gain, and unclear signs of clinical success as the greatest impediments to patient compliance with T2D treatment. 53.7% (n = 200/373) of HCPs polled considered risk of patient weight gain and hypoglycemia a primary factor in their treatment decision. The majority of respondents (56.4%; n = 201/373) considered the relationship between glycemic control, weight loss, and minimizing the risk of hypoglycemic events strongly related to their treatment decisions. When asked about the impact weekly GLP-1 treatments would have on their treatment utilization, 36.8% (n = 137/373) said daily GLP-1 analogs, followed by basal insulin (22.8%, n = 85/373) and metformin (19.3%, n = 72/373). Healthcare providers treating T2D face a number of interrelated challenges, including weight control, glycemic control, and treatment adherence. Despite increasing treatment availability, HCPs polled in this survey remained unsatisfied with their current treatment options.